Daniela A. Bota, MD, medical director of Neuro-Oncology at University of California Irvine, discusses the findings from a dose-escalation trial of marizomib.
Daniela A. Bota, MD, medical director of Neuro-Oncology at University of California Irvine, discusses the findings from a dose-escalation trial of marizomib.
According to the results, marizomib is a well-tolerated drug amongst patients with newly diagnosed glioblastoma. The recommended dose identified in this trial was 0.8 mg/m2. The drug will be administered at days 1, 8, and 15 in a 28-day cycle, Bota explains.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More